• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 100
  • 60
  • 12
  • 6
  • 3
  • 2
  • 2
  • 1
  • 1
  • Tagged with
  • 224
  • 46
  • 36
  • 33
  • 32
  • 31
  • 22
  • 21
  • 21
  • 21
  • 21
  • 18
  • 17
  • 15
  • 15
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
151

Modelagem farmacocinética-farmacodinâmica da piperacilina em ratos imunodeprimidos infectados com Escherichia coli

Araújo, Bibiana Verlindo de January 2002 (has links)
Objetivos: Avaliar a adequabilidade do modelo farmacocinético-farmacodinâmico (PK-PD) (NOLTING et al., 1996b) para modelar o efeito bactericida da piperacilina (PIP) em ratos Wistar infectados experimentalmente com Escherichia coli ATCC 25922. Metodologia: Experimentos de Farmacocinética: Determinou-se as concentrações plasmáticas totais e livres teciduais de PIP, através de microdiálise (MD), após administração de 240 mg/kg i.v. bolus a ratos Wistar granulocitopênicos (ciclofosfamida) infectados no músculo esquelético (105 UFC/mL) com E. coli. As amostras de plasma e de MD foram analisadas por CLAE. As sondas de MD foram calibradas por retrodiálise. Experimentos de Farmacodinâmica: Os animais imunodeprimidos e infectados foram tratados com PIP nas doses de 120 ou 240 mg/kg, em intervalos de 4/4, 6/6 e 8/8 horas por 24 h. Em tempos pré-determinados, os animais foram sacrificados (n = 3/tempo), o músculo infectado foi retirado, homogeneizado e o número de UFC/mL foi determinado em placas de ágar-sangue, após diluições sucessivas. Um grupo não tratado foi utilizado como controle. Modelagem PK-PD: A partir dos dados farmacocinéticos e farmacodinâmicos obtidos, avaliou-se efeito de morte bacteriana em função do tempo com o auxílio do programa de regressão não-linear SCIENTIST® v.2.0. Resultados e Discussão: Os parâmetros farmacocinéticos após a administração de PIP (240 mg/kg) foram t½ de 40 ± 8 min; CL de 0,46 ± 0,021 (L/h/kg) e um Vdss de 0,30 ± 0,06 L/kg. O perfil de PIP livre tecidual foi previsto a partir dos parâmetros plasmáticos utilizando ajuste simultâneo dos dados de plasma e tecido e um fator de proporcionalidade de 0,342 ± 0,101. Os parâmetros do modelo PK-PD obtidos foram: EC50 de 1,31 ± 0,27 μg/mL e kmax 1,39 ± 0,20 h-1. Os valores dos parâmetros da modelagem PK-PD obtidos in vivo diferiram dos descritos na literatura para o mesmo antibiótico e bactéria quando simulados in vitro. Conclusões: O modelo Emax-modificado descreveu os perfis de crescimento e morte bacteriana em função do tempo obtidos nas diferentes posologias testadas sendo adequado para modelagem PK-PD da piperacilina nas condições experimentais investigadas. / Purpose: The objective of this study was to model the killing effect of a β-lactam antibiotic, piperacillin (PIP), in neutropenic and E. coli ATCC 25922 infected rats after different dosing regimens using a modified Emax PK-PD model. Methodology: Pharmacokinetic studies: Total plasma and free tissue concentrations of PIP, determined by microdialysis, were investigated after i.v. bolus of 240 mg/kg of the drug to immunecompromised (cyclophosphamide) and E. coli infected (107 CFU) Wistar rats. Microdialysis probes recoveries were determined by retrodialysis. Plasma and tissue samples were analyzed by HPLC. Pharmacodynamic studies: The infected rats were treated with iv bolus PIP 120 mg/kg or 240 mg/kg q8h, q6h, q4h. Three animals were sacrificed at predetermined times up to 24 hours. The infected muscle was removed, homogenized and the number of CFU/mL was determined by plate counting after 24 hours of incubation at 37ºC. A control group without treatment was used. PK-PD modeling: PIP killing effect as a function of time was fitted using the Emax-modified model with the aid of a non-linear regression computer program SCIENTIST® v.2.0. Results and Discussion: The pharmacokinetic parameters determined for PIP 240 mg/kg iv bolus were: t½ of 40 ± 8 min; CL of 0.46 ± 0.021 (L/h/kg) and Vdss of 0.30 ± 0.06 L/kg. Piperacillin free tissue levels were predicted using plasma data ina a simultaneous fitting with a proportionality factor of 0.342 ± 0.101. The parameters derived from PK-PD modeling were: bacterial killing rate (kmax) of 1.39 ± 0.20 h-1 concentration to produce 50% of de maximum effect (EC50) of 1.31 ± 0.27 μg/mL. The PK-PD parameters determined in vivo were different from those reported for the same bacteria and drug in vitro. Conclusions: The Emax model adequately described PIP antibacterial effect in animals for the different dosing regimens investigated.
152

Modelagem farmacocinética/farmacodinâmica do antifúngico fluconazol / Pharmacokinetic/pharmacodynamic modeling of the antifungal fluconazole

Azeredo, Francine Johansson January 2013 (has links)
Objetivos: O objetivo deste trabalho foi o estabelecimento de um modelo PK/PD capaz de descrever o efeito fungistático de fluconazol (FCZ) contra diferentes espécies de Candida. Método: a fim de atingir esse objetivo, as seguintes etapas foram realizadas: i) métodos bioanalíticos foram desenvolvidos e validados em CL-EM/EM e CLAE/UV para a determinação do FCZ em plasma e microdialisado renal de rato, respectivamente; ii) a verificação das condições da microdiálise do FCZ e sua recuperação in vitro pelos métodos da diálise (RRD) e retrodiálise (RRE) e in vivo por RRE; iii) avaliação das concentrações livres de FCZ no rim de ratos Wistar saudáveis e infectados por Candida albicans através do uso da microdiálise após a administração de 10 mg/kg de FCZ pela via intravenosa e de 50 mg/kg de FCZ pela via oral, a fim de estabelecer a relação entre os níveis livres renais e plasmáticos totais do FCZ em ambas as condições, iv) a modelagem PK/PD do efeito fungistático do FCZ contra Candida albicans, Candida parapsilosis e Candida tropicalis empregando o modelo de Emax-modificado e a determinação de seus parâmetros PK/PD utilizando um modelo de infecção in vitro, em que as concentrações renais livres de FCZ esperadas em seres humanos após diferentes posologias foram simuladas: a) concentrações flutuantes do fármaco - 200, 400 e 800 mg q8h, q12h e q24h - e concentrações constantes, múltiplas da concentração inibitória mínima (CIM) – 0,5, 1, 2, 4 e 8 vezes a CIM. Os dados de farmacocinética e farmacodinâmica foram modelados com o auxílio do software Scientist®. Resultados e Conclusões: i) os métodos analíticos para quantificação do FCZ foram desenvolvidos e validados, sendo específicos, exatos e precisos, com limites de quantificação de 100 ng/mL e 10 ng/mL para detecção em plasma e microdialisado, respectivamente, ii) as recuperações determinadas in vitro por RRD e RRE foram independentes do fluxo e da concentração. Os valores de recuperação das sondas de microdiálise determinada in vitro por RRD (53,4 ± 2,3%) e RRE (54,2 ± 1,8%) e in vivo por RRE (49,7 ± 2,2%) foram estatisticamente semelhantes nas condições experimentais investigadas (α = 0,05), indicando que o FCZ é um fármaco adequado para ser avaliado por esta abordagem; iii) não houve diferença estatística na área sob a curva de concentração versus tempo (AUC 0-∞) renal livre e plasmática total em ratos Wistar, saudáveis ou infectados por Candida albicans, pela mesma via de administração investigada. A penetração renal do FCZ foi semelhante para ambas as doses nas condições investigadas (variando entre 0,77 e 0,84) e a sua fração plasmática livre, determinada por microdiálise, foi independente da concentração (86,0 ± 2,0%). Utilizando as equações farmacocinéticas apropriadas, os parâmetros plasmáticos farmacocinéticos determinados foram capazes de prever os valores de concentrações livres renais em ratos sadios e infectados, assumindo que a ligação a proteínas plasmáticas é conhecida. Além disso, a candidíase sistêmica não interfere na penetração renal do FCZ, indicando que as suas concentrações plasmáticas livres são boas preditoras do valor de concentração tecidual livre (farmacologicamente ativa) em animais sadios e infectados, podendo ser utilizada para estabelecer e otimizar os regimes posológicos do FCZ para o tratamento de candidíase disseminada; iv) a concentração que causa 50% do efeito fungistático máximo (CE50) do FCZ foi estatisticamente menor para C. albicans (4.4 ± 1.4 μg/mL) do que para C. parapsilosis e C. tropicalis, 8.1 ± 1.6 μg/mL e 8.3 ± 1.8 μg/mL respectivamente, ao simular-se diferentes regimes de dose, bem como concentrações constantes do fármaco (CE50, C. albicans = 3.5 ± 1.3 μg/mL; CE50, C. parapisolosis = 6.1 ± 1.2 μg/mL; CE50, C. tropicalis = 6.5 ± 1.2 μg/mL) (α = 0.05). A taxa de morte fúngica (kmax) foi estatisticamente semelhante para todas as espécies de Candida estudadas. (aproximadamente 0,4 h-1) e sempre estatisticamente menor do que a taxa de crescimento fúngico, k0 (aproximadamente de 2 h-1) (α = 0,05). O modelo PK/PD foi capaz de descrever o efeito fungistático do FCZ contra as três espécies de Candida investigadas in vitro. O FCZ se mostrou igualmente eficaz contra essas leveduras, porém sua potência foi maior frente a C.albicans do que frente a C. parapsilosis e C. tropicalis. O modelo PK/PD utilizado pode ser empregado para simular esquemas posológicos alternativos, para comparar o efeito farmacológico do FCZ com o efeito de outros antifúngicos e, finalmente, para otimizar a terapia deste fármaco para o tratamento de candidíase sistêmica. / Objective: The aim of this work was the development of a pharmacodynamic/pharmacokinetic (PK/PD) model able to describe the fungistatic effect of fluconazole (FCZ) against Candida spp. Method: in order to reach this objective, the following steps were realized: i) bioanalytical methods were developed and validated in LC-MS/MS and HPLC/UV for determination FCZ in rat plasma and kidney microdialisate, respectively; ii) analysis of microdialysis of FCZ conditions and its recovery in vitro by dialysis (RRD) and retrodialysis (RRE) methods and in vivo by RRE; iii) evaluation of free levels of FCZ in the kidney of healthy and Candida albicans infected Wistar rats using microdialysis, after a 10 mg/kg i.v. dosing and 50 mg/kg oral dosing in order to establish the relationship between free renal and total plasma levels in both conditions; iv) the fungistatic pharmacological effect of FCZ against Candida albicans, Candida parapsilosis and Candida tropicalis ATCC strains by pharmacokinetic/pharmacodynamic (PK/PD) modeling of the time–kill curves employing an Emax model was determined using an in vitro infection model, where the free kidney concentrations of FCZ in humans after different posologies were simulated: a) fluctuating drug concentrations - 200, 400 and 800 mg q8h, q12h e q24h – and constant concentrations, multiples of the minimum inhibitory concentrations (MIC) – 0,5, 1, 2, 4 and 8 times the MIC. The pharmacokinetic and pharmacodynamic data were modeled with the software Sientist®. Results and Conclusions: i) the analytical methods developed were specific, precise, and accurate with limits of quantification of 100 ng/mL and 10 ng/mL for microdialisate and plasma, respectively; ii) the recoveries determined by RRD and RRE in vitro were concentration independent and flow rate dependent on the ranges investigated. The recoveries determined in vitro by RRD (53.4 ± 2.3%) and RRE (54.2 ± 1.8%) and in vivo by RRE (52.3 ± 2.3%) were statistically similar under the experimental conditions investigated (α = 0.05), indicating that FCZ is a suitable drug to be evaluated by microdialysis; iii) There were no statistical differences between the area under the free concentration-time curve (AUC 0–∞) in plasma and in tissue for either healthy or infected groups for the same dose regimen investigated. The antifungal tissue penetration was similar for both doses and all conditions investigated (ranging from 0.77 to 0.84). Unbound FCZ plasma fraction, determined by microdialysis, was concentration-independent (86.0 ± 2.0%). Using appropriate equations, pharmacokinetic (PK) parameters determined by fitting plasma concentration-time profiles were able to predict free renal levels.The results showed FCZ easily penetrates the kidney and PK parameters determined in plasma can be used to predict free tissue levels of the drug assuming the drug protein binding is known. Furthermore, systemic candidiasis does not interfere with the drug kidney penetration, indicating that free plasma concentrations are a good surrogate for active levels in both healthy and infected kidney and can be used to establish and optimize FCZ dosing regimens to treat disseminated candidiasis; iv) FCZ concentration necessary to produce 50% of the maximal fungistati effect (EC50) was statiscally smaller against C. albicans (4.4 ± 1.4 μg/mL) than against C. parapsilosis and C. tropicalis, 8.1 ± 1.6 μg/mL and 8.3 ± 1.8 μg/mL respectively, when simulating multiple dosing regimens as well as constant concentrations (EC50, C. albicans = 3.5 ± 1.3 μg/mL; EC50, C. parapisolosis = 6.1 ± 1.2 μg/mL; EC50, C. tropicalis = 6.5 ± 1.2 μg/mL) (α = 0.05). The maximum killing rate constant (kmax) was statistically similar for the Candida spp. (approximately 0.4 h-1) and always statistically smaller than the natural grown rate k0 (approximately 2 h-1) (α = 0.05). The PK/PD model was able to describe the fungistatic effect of fluconazole in vitro against the three Candida spp investigated. Fluconazole showed equivalent efficacy against these yeasts and higher potency against C. albicans than against C. parapsilosis and C. tropicalis. The model can be used to simulate alternative regimens, to compare its pharmacological effect with other antifungals and to optimize FCZ therapy to treat systemic candidiasis.
153

Modelagem farmacocinética-farmacodinâmica de antifúngicos azólicos em animais infectados por Cryptococcus neoformans / Pharmacokinetic-pharmacodynamic modeling of azoles antifungals in Cryptococcus neoformans infected animals

Alves, Izabel Almeida January 2017 (has links)
O objetivo desta tese foi desenvolver um modelo farmacocinético-farmacodinâmico (PK-PD) aplicável a avaliação de esquemas posológicos de antifúngicos sistêmicos no tratamento de infecções cerebrais associadas ao Cryptococcus neorformans. Inicialmente um modelo de infecção cerebral em ratos Wistar machos imunocompetentes foi estabelecido. Os animais foram inoculados a partir da administração iv de 1.106 UFC/mL na veia lateral caudal, de uma cepa de Cryptococcus neoformans var neoformans (ATCC 28957). A presença da levedura em cérebro, pulmão, fígado, rins e coração foi avaliada após 7, 10 e 14 dias. Paralelamente foram investigados os parâmetros bioquímicos (contagem de leucócitos, TGO, TGP, uréia, creatinina, albumina e CK) e a permeabilidade vascular cerebral com azul de Evans. Após 10 dias de inoculação foi produzida uma infecção com características semelhantes a doença em humanos. C. neoformans esteve presente em todos os tecidos investigados pelas análises histológicas e microbiológicas e diferenças nos níveis de albumina, ureia, TGP e CK, alteração no número de leucócitos (monócitos e neutrófilos) e elevação da permeabilidade cerebral ao azul de Evans foram observadas nos animais infectados. Após estabelecida e caracterizada a infecção, foi avaliada a farmacocinética plasmática e tecidual cerebral através da técnica de microdiálise, do fluconazol (FLU) (20 mg/kg, i.v. bolus) e do voriconazol (VRC) (5 mg/kg, i.v. bolus) em ratos Wistar sadios (n = 13) e infectados (n = 13). De posse dos dados das concentrações plasmáticas e teciduais vs tempo dos grupos sadios e infectados construiu-se um modelo farmacocinético populacional (PopPK) para cada fármaco investigado. A penetração cerebral do VRC demonstrou-se elevada nos animais infectados (fTsadios = 0,85 vs fTinfectados = 1,86). O modelo PopPK de dois compartimentos e eliminação por Michaelis Menten descreveu o perfil de concentrações versus tempo de VRC em plasma e tecido, simultaneamente. A covariável infecção foi incluída em V2 e VM. Observou-se o grande potencial do VRC para tratar meningite associada a C. neoformans, pois os níveis alcançados em tecidos infectados foram superiores aos valores descritos para CIM de VRC contra C. neoformans (0,03 - 0,5 μg/mL). A farmacocinética do FLC foi descrita através de um modelo PopPK de dois compartimentos com eliminação linear incluindo dados de concentrações plasmáticas e livres cerebrais para ambos os grupos investigados. Nesse modelo a covariável infecção foi atribuída ao parâmetro k21 e covariável peso foi atribuída aos parâmetros V1 e V2. De posse desse modelo popPK, foram investigados os desfechos farmacodinâmicos considerando o nível de exposição cerebral nas doses de 125 e 250 mg/kg para ratos e 400-2000 mg para humanos observado em tecido sadio e infectado através da probabilidade de atingir o alvo terapêutico (PTA - fASC/CIM = 389) do FLC usando simulações de Monte Carlo. Essas simulações demonstraram um uso limitado de fluconazol em monoterapia para o tratamento de meningite por C. neoformans. Após a etapa farmacocinética procederam-se os estudos farmacodinâmicos através da metologia de curvas de morte em função do tempo do fluconazol e voriconazol frente a C. neoformans. Os dados da curva de morte foram modelados adequadamente com o modelo PK-PD de Emax modificado incluindo um termo de atraso de crescimento. A CIM foi determinada para ambos os fármacos por microdiluição e os valores foram de 0,03 μg/mL para voriconazol e 0,5 μg/mL para fluconazol, indicando que esta cepa ATCC 28957 é sensível a ambos os fármacos. Os valores de k, EC50 e kmax foram determinados para vários múltiplos das CIM de cada fármaco (0,03×, 0,06×, 0,25×, 0,5×, 1× 4×, 16×, 32× e 64×). O valor médio de k foi de 0,38 h-1, EC50 foi de 1,26 ± 0,18 μg/mL e 0,32 ± 0,06 μg/mL e kmax foi de 0,95 ± 0,21 h-1 e 0,64 ± 0,12 h-1 para FLC e VRC, respectivamente. Por fim, de posse dos parâmetros calculados através do modelo PK-PD foram realizadas simulações dos desfechos de tratamento para meningite criptocócica no cenário clínico para ambos os fármacos após administração das doses 200 e 400 mg de voriconazol e 800 e 2000 mg de fluconazol por dez semanas. Através das simulações conclui-se que para fluconazol há 25% de insucesso na dose de 800 mg e 10% na dose de 2000 mg com um tempo médio de 3 semanas para erradicação da levedura. Para o voriconazol, o EC50 teve pouco impacto sobre a erradicação do fungo e, em todos os cenários foi observada uma erradicação completa do fungo em curto espaço de tempo (1 - 2 semanas). Os resultados incentivam o uso de voriconazol nos pacientes com meningite criptocócica e uma reavaliação do uso de fluconazol. / The aim of this thesis was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model for the evaluation of systemic antifungal dosing regimens for the treatment of brain infections associated with Cryptococcus neorformans. Firstly a model of brain infection in immunocompetent male Wistar rats was established. The animals were inoculated by intravenously administration of 1. 106 CFU/mL of Cryptococcus neoformans var neoformans (ATCC 28957) into the tail lateral vein. The presence of yeasts in the brain, lung, the liver, kidneys and the heart was evaluated after 7, 10 and 14 days. The biochemical parameters (leucocytes counting, GOT, GPT, urea, creatinine, albumin and CK) and cerebral vascular permeability with Evans blue were investigated. After 10 days post inoculation an infection with characteristics similar in humans was produced. C. neoformans was present in all tissues investigated by histological and microbiological analyzes and differences in albumin, urea, GPT and CK levels, alterations in the number of leukocytes (monocytes and neutrophils), and elevation of cerebral permeability to Evans blue were observed in infected animals. After establishing and characterizing the infection, the plasma and cerebral tissue pharmacokinetics were evaluated by microdialysis after administration of fluconazole (FLU) (20 mg/kg, iv bolus) and voriconazole (VRC) (5 mg/kg, iv bolus) in healthy (n = 13) and infected Wistar rats (n = 13). A population pharmacokinetic model (PopPK) was build for each drug, based on data from plasma and tissue concentrations vs. time of healthy and infected groups. The brain penetration of voriconazole was shown to be high in infected animals (fThealthy = 0.85 vs fTinfected = 1.86) than in healthy ones. The two-compartment model with Michaelis Menten elimination best described the concentration of VRC in plasma and tissue. The covariate infection was included in V2 and VM. The great potential of voriconazole to treat meningitis associated with C. neoformans was observed, as the levels reached in infected tissues were higher than the values described for MIC against C. neoformans (0.03 - 0.5 μg/mL). The pharmacokinetics of FLC was described using a two-compartment model with linear elimination including data from plasma and brain free concentrations for both groups investigated. In this model the covariate infection was attributed to parameter k21 and covariate weight was assigned to parameters V1 and V2. With this popPK model, the pharmacodynamic outcomes were investigated considering the level of brain exposure at doses of 125 and 250 mg/kg for rats and 400 - 2000 mg for humans observed in healthy and infected tissue through the probability of attaining the target (PTA - fAUC/MIC = 389) of fluconazole using Monte Carlo simulations. These simulations demonstrated limited use of fluconazole in monotherapy for the treatment of C. neoformans meningitis. After the pharmacokinetics modeling, the pharmacodynamic studies were carried out using the methodology of time-kill curves of fluconazole and voriconazole versus C. neoformans. The kill curves data were suitably modeled with the modified Emax PK-PD model including a growth delay term. MIC was determined for both drugs by microdilution and values were 0.03 μg.mL-1 for voriconazole and 0.5 μg.mL-1 for fluconazole, indicating that this ATCC 28957 strain is sensitive to both drugs. The values of k, EC50 and kmax were determined for several MIC multiples of each drug (0.03 ×, 0.06 ×, 0.25 ×, 0,5×, 1 × 4 ×, 16 ×, 32 × and 64 ×). The mean value of k was 0.38 h-1, EC50 was 1.26 ± 0.18 μg.mL-1 and 0.32 ± 0.06 μg.mL-1 and kmax was 0.95 ± 0.21 h -1 and 0.64 ± 0.12 h-1 for FLC and VRC, respectively. Finally, the parameters obtained using the PK-PD model were used to simulate treatment outcomes for cryptococcal meningitis in the clinical setting for both drugs after administration of 200 and 400 mg of voriconazole and 800 and 2000 mg of fluconazole for 10 weeks. By the simulations it is concluded that for fluconazole there is a 25% rate of failure at the dose of 800 mg and 10% at the dose of 2000 mg with an average time of 3 weeks for eradication of the yeast. For voriconazole, the EC50 had little impact on fungus eradication and, in all scenarios complete eradication of the fungus was observed in a short time (1 - 2 weeks). The results encourage the use of voriconazole in patients with cryptococcal meningitis and a reassessment of fluconazole use.
154

Monitoring the first stages of the regeneration of bone defects

Gao, Wenling 06 July 2016 (has links) (PDF)
The different strategies of tissue engineering for functional reconstruction of critical-size bone defects require a thorough knowledge of physiological mechanisms of bone repair. Bone healing is a complex process affected by various mediators. Several investigations have studied the gene expression 1 to 3 days after an acute or experimental fracture. Little is known about the humoral and cellular in vivo reaction in the early stages of bone healing. In contrast to other methods of molecule sampling and detection, which usually lead to the inhibition of the biological activity following complex sample preparation and quantification, microdialysis is a real-time monitoring technique which can be applied in living tissues providing a strong link between analytical methodology and biochemistry. In this study, the optimal conditions for microdialysis in a critical size rat long bone defect model for both in vivo and in vitro analyses were developed. Mediators and components of the extracellular matrix occurring in the first 24 to 48 hours of bone healing locally and systemically were monitored via microdialysis and blood sampling, respectively. Furthermore, novel proteins and their modulation were explored during this time frame. In vitro microdialysis was used to optimize the condition for protein recovery. Addition of bovine serum albumin (BSA) resulted in an enhanced recovery of interleukin (IL)-6. The maximal relative recovery (RR) was from 15.0% without BSA and 23.6% with BSA, while the maximal RR of transforming growth factor (TGF)-β1 was 11.2% with BSA and the concentration of TGF-β1 was below the detection limit of enzyme-linked immunosorbent assay (ELISA) without BSA. Using in vivo microdialysis, total protein concentrations varied between 0.20±0.12 mg/mL and 0.44±0.18 mg/mL. Among the mediators produced in the fracture hematoma within 24 h after the injury, IL-6 was secreted with the highest concentration of 309.1 pg/mL between 12 and 15 h after creation of the critical size bone defect. Meanwhile, the detectable concentrations of TGF-β1 in microdialysates ranged from 3.6 to 44.0 pg/mL and in blood plasma TGF-β1 was constantly producted ranging from 656.3 to 8398.2 pg/mL for 24 h after bone defct. Moreover, another constant producted growth factor in blood plasma was PDGF-BB and the concentration ranged from 222.1 to 589.4 pg/mL for 8 h after bone defect. Using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), 36 proteins were identified in the microdialysates over 8 h, and 884 proteins were identified on probes which were implanted into the bone defect over 24 h. Among the proteins identified in the hematoma, only a minority originated from the extracellular space. Protein analysis indicated five pathways associated with bone healing that were overrepresented after creating soft tissue and bone defects, of which FGF signaling was specific for bone defects. Furthermore, C-X-C motif ligands CXCL-1, CXCL-2, CXCL-3, CXCL-4, CXCL-5, CXCL-7, rodent bone protein (RoBo-1), insulin-like growth factor (IGF)-I, and chitinase-3-like protein 1 were detected in the fracture hematoma. These proteins are potentially associated to early bone healing. As seen by histological analysis, polymorphonuclear leukocytes (PMNs) and lymphocytes penetrated into the fracture hematoma immediately after surgery and peaked at 24 h. This study for the first time presents data from both the local and systemic acute response to bone and soft tissue injury in a small animal model. The results of mcrodialysis sampling may serve as a baseline for future investigations on different models and time frames. Several proteins and pathways have been identifeid as potentially important for early bone regeneration warranting in depth analysis in further studies. / Zur Entwicklung neuer Strategien der Geweberegenerierung in kritischen Knochendefekten, die sich durch Selbstheilungsprozesse nicht schließen, ist das Verständnis der beteiligten physiologischen Prozesse essentiell. Der Wiederaufbau von Gewebe, wie etwa während Knochenheilungsprozesse ist komplex reguliert und erfordert das koordinierte Zusammenspiel einer Vielzahl von Zellen und Mediatoren. Obwohl bereits in zahlreichen Studien die Veränderungen in der Genexpression in den ersten 3 Tagen nach einer akuten oder experimentell induzierten Fraktur untersucht wurden, ist noch immer wenig über die zellulären und humoralen Vorgänge in den frühen Phasen der Knochenheilung in vivo bekannt. Gebräuchliche Analysemethoden erfordern komplexe Verfahren zur Probenentnahme und Nachweisreaktionen währenddessen die biologische Aktivität der untersuchten Mediatoren häufig graduell verloren geht. Die Mikrodialyse hingegen kann in Echtzeit am lebenden Objekt und am Ort der Verletzung durchgeführt werden und bildet somit eine erfolgsversprechende Plattform um die Probengewinnung noch enger mit der anschließenden biochemischen Nachweistechnik zu verbinden. Im Rahmen dieser Arbeit wurden die optimalen Konditionen zur Mikrodialyse erstmals an einem kritischen Defektmodell eines Ratten-Röhrenknochens zur in vivo und in vitro Applikation ermittelt. Dazu wurde das Vorkommen verschiedener Komponenten der extrazellulären Matrix und ausgewählter Mediatoren während der ersten 24 bis 48 Stunden der Knochenheilung überwacht. Neben der durch Mikrodialyse gewonnenen Proben wurden auch Blutproben verarbeitet um sowohl die lokale, als auch systemische Konzentration der untersuchten Proteine zu erfassen. Durch eine Proteomanalyse konnten zudem bislang in diesem Prozess unbekannte Moleküle identifiziert und verfolgt werden. Zur Optimierung der Mikrodialyse wurden zunächst die Bedingungen hinsichtlich der Proteinrückgewinnung verbessert. Durch den Zusatz von Rinderserumalbumin (BSA) konnte die Rückgewinnung von Interleukin (IL)-6 erhöht werden. Die maximale relative Rückgewinnung (RR) konnte von 15.0% ohne BSA auf 23.6% mit BSA gesteigert werden. Noch dramatischer war dieser Effekt für den transforming growth factor (TGF)-β1 von dessen eingesetzter Menge in vitro 11.2% detektiert werden konnte, während in der BSA-freien Dialyselösung kein TGF-β1 nachgewiesen wurde. Die RR blieb stets unter der Detektionsgrenze des verwendeten enzyme-linked immunosorbent assay (ELISA). In vivo-Dialysate enthielten totale Proteinkonzentrationen zwischen 0,20±0,12 mg/mL und 0,44±0,18 mg/mL. Von den innerhalb von 24 h nach Verletzung im Frakturhämatom produzierten Mediatoren wurde IL-6 am stärksten exprimiert. Die höchsten Konzentrationen (309,1pg/mL) konnten hierfür nach 12 bis 15 Stunden nach Einführung des Defekts gemessen werden. Die Konzentrationslevel von TGF-β1 hingegegen betrug nur 3,6 bis 44,0 pg/mL.Mittels high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), konnten 36 Proteine in den über 8 Stunden gewonnenen Mikrodialysaten, und 884 Proteine von Explantaten, die 24 h im Knochendefekt integriert waren, identifiziert werden. Von den im Frakturhämatom identifizierten Proteinen war nur eine Minderheit extrazellulären Ursprungs. Durch die Proteomanalyse konnten fünf Signalwegskaskaden identifiziert werden. Von diesen trat „FGF (fibroblast growth factor) signaling“ ausschließlich in Knochendefekten, nicht jedoch in den zur Kontrolle mitgeführten reinen Weichgewebedefekten auf. Im Frakturhämatom konnten die, C-X-C motif-Liganden CXCL-1, CXCL-2,CXCL-3, CXCL-4, CXCL-5, CXCL-7, rodent bone protein (RoBo-1), insulin-like growth factor (IGF)-I, und das chitinase-3-like protein 1 nachgewiesen werden. Die identifizierten Proteine könnten von Bedeutung für die Steuerung früher Knochenheilungsprozesse sein. Histologische Untersuchungen zeigten, dass polymorphkernige Leukozyten (PMNs) und Lymphozyten sofort nach der Operation in das Frakturhämatom einwandern und ihre Anzahl nach etwa 24 h ihr Maximum erreicht. Diese Studie präsentiert erstmals Daten der lokal und systemisch ablaufenden zellulären und humoralen Vorgänge als Antwort auf einen Weichgewebs-bzw. Knochendefekt in einem Nagetier-Kleintiermodell. Die Mikrodialyse-Resultate stellen eine vielversprechende Grundlage für zukünftige Untersuchungen in anderen Modellen dar. Außerdem bilden die hier identifizierten Proteine und Signalwege eine Gruppe potenter Kandidaten für weiterführende Untersuchungen zur Knochenregeration.
155

Modelagem farmacocinética-farmacodinâmica do antifúngico voriconazol

Araújo, Bibiana Verlindo de January 2008 (has links)
Objetivos: O objetivo deste trabalho foi o desenvolvimento de um modelo farmacocinético/farmacodinâmico (PK/PD) para descrever o efeito antifúngico voriconazol (VRC) contra espécies de Candida. Método: Para alcançar este objetivo as seguintes etapas foram realizadas: i) foi adaptado e padronizado modelo de candidíase disseminada em ratos Wistar imunocompetentes e imunocomprometidos com Candida sp.; ii) foram validados métodos analíticos de LC-MS/MS e LC-UV para o doseamento do VRC em amostras de plasma e microdialisado de tecido; iii) foram estabelecidas as condições para microdiálise do VRC e as taxas de recuperação in vitro, por perda e ganho, e em tecido renal in vivo, por retrodiálise, foram determinadas; iv) foi avaliada a PK não-linear do VRC após administração i.v. bolus das doses de 2,5, 5 e 10 mg/kg e a biodisponibilidade oral foi determinada em roedores; v) a penetração renal do VRC após administração oral das doses de 40 e 60 mg/kg foi determinada em ratos Wistar sadios e infectados com C. albicans ou C. krusei; e (vi) o perfil fungistático do VRC contra C. albicans e C. krusei foi determinado utilizando modelo de infecção experimental in vitro onde foram simuladas as concentrações livres renais do VRC esperadas em humanos após administração oral e i.v. de diferentes posologias. Os dados de cinética e dinâmica obtidos foram modelados com equação de Emax modificada, com auxílio do Scientist®. Resultados e Conclusões: i) O modelo de candidíase disseminada foi adaptado com sucesso para ratos Wistar. C. albicans apresentou maior virulência com Log UFC/g de tecido renal de 5,51 ± 0,56 e 7,29 ± 0,26, após 2 e 7 dias de infecção em animais imunocompetentes, respectivamente. Em animais imunocomprometidos a contagem foi de 6,43 ± 0,59 Log UFC/g após 2 dias de infecção, com morte de todo o grupo dentro de 4 dias. As espécies não-albicans (C. krusei e C. glabrata) apresentaram um perfil de infecção semelhante em animais imunocompetentes (Log UFC/g = 2,98 ± 0,27 para C. krusei e 2,48 ± 0,46 para C. glabrata). Entretanto, nos animais imunocomprometidos, C. krusei promoveu morte de todo o grupo em até 7 dias, enquanto C. glabrata causou apenas um aumento no grau de infecção (Log UFC/g = 6,98 ± 0,48). ii) Os métodos analíticos por LC-UV e LCMS/ MS para quantificação do VRC foram validados. As curvas de calibração foram lineares na faixa de 50 a 2500 ng/mL (r > 0,98) para ambos os métodos. Os ensaios de precisão intra e inter-dia foram > 94,9 e 95,8 %, para microdialisado por HPLC-UV e > 87,5 e 92,3 % para LC-MS/MS em plasma, respectivamente. A exatidão foi > 89,1 % para HPLC-UV e > 88,4 % para LC-MS/MS. iii) A avaliação do VRC por microdiálise mostrou que a recuperação é concentração independente (0,1–2,0 μg/mL). O VRC entretanto, devido a sua moderada lipofilia, liga-se às tubulações do sistema de microdiálise, gerando diferenças entre a recuperação determinada pelo método de perda (retrodiálise) e de ganho (diálise) in vitro, as quais puderam ser corrigidas após o cálculo do coeficiente de ligação do fármaco ao sistema. A recuperação in vivo após correção da ligação ao sistema foi de 24,5 ± 2,8 % iv) A análise dos perfis de plasmáticos do VRC obtidos em ratos Wistar após administração oral mostrou comportamento não-linear, compatível com saturação de eliminação. A avaliação compartimental dos perfis i.v. de diferentes doses, utilizando modelo de três compartimentos com eliminação de Michaelis-Menten, permitiu a determinação da constante de Michaelis (KM) de 0,58 μg/mL e da velocidade máxima da eliminação (VM) de 2,63 μg/h, em média. A modelagem simultânea dos dados plasmáticos (40 mg/kg) e i.v. (10 mg/kg) permitiu a determinação da biodisponibilidade oral do VRC em ratos, que foi de 82,8%. v) A fração de penetração renal do VRC, determinada por microdiálise em ratos sadios e infectados, foi de 0,34 ± 0,01, similar a fração livre do fármaco no plasma (0,34), indicando que as concentrações livres renais de VRC são semelhantes às concentrações livres plasmáticas e que as mesmas não se modificam devido a infecções causadas por Candida sp. vi) Os parâmetros da modelagem PK/PD do efeito do VRC contra espécies de Candida em modelo de infecção experimental in vitro obtidos foram: CE50 de 2,96 μg/mL e Kmax = 0,26 h-1 para C. albicans e CE50 de 3,47 μg/mL e Kmax = 0,51 h-1 para C. krusei. Houve diferença estatística apenas no Kmax para as duas espécies (α = 0,05) indicando uma maior suscetibilidade da C. krusei ao VRC. O modelo PK/PD de Emax modificado utilizado foi capaz de descrever adequadamente os perfis de inibição do crescimento de Candida sp em função do tempo, para todos os regimes terapêuticos do VRC avaliados, podendo ser usado para otimização da terapia com esse fármaco. / Objectives: The aim of this work was the development of a pharmacokineticpharmacodynamic model (PK/PD) to describe the fungistatic effect of voriconazole (VRC) against Candida species. Method: To reach this objective, the following steps were done: i) a disseminated candidiasis model to immunocompetent and immunocompromised Wistar rats with Candida sp was adapted and standardized; ii) analytical methods of LC-MS/MS and LC-UV for measurement of VRC in plasma and microdialysate tissue samples were validated; iii) microdialysis conditions of VRC and the recoveries rate in vitro, by loss and gain, in renal tissue in vivo, by retrodialysis, were determined; iv) the non-linear PK of VRC after i.v. bolus administration of 2.5, 5 e 10 mg/kg doses were evaluated and the oral bioavailability in rodents was estimated; v) tissue penetration of VRC after oral administration of 40 and 60 mg/kg was determined in healthy and infected by C. albicans or C. krusei Wistar male rats; vi) the fungistatic profile of VRC against C. albicans and C. krusei was determined using a experimental infection model in vitro, where the free renal concentrations of VRC expected in humans after oral and iv administration of different dosing regimens were simulated. The kinetic and dynamic data obtained were modeled using an Emax modified model, with aid of Scientist®. Results and Conclusions: i) The disseminated candidiasis model was successfully adapted to Wistar rats. C. albicans showing high virulence with Log CFU/g of renal tissue of 5.51 ± 0.56 and 7.29 ± 0.26, after 2 and 7 days of infection in immunocompetent animals, respectively. In immunocompromised animals, the counting was 6.43 ± 0.59 Log CFU/g after 2 days of infection, with whole group death within 4 days. Non-albicans especies (C. krusei e C. glabrata) showed a similar infection profile in immunocompetent and immunocompromised animals (Log CFU/g = 2.98 ± 0.27 to C. krusei e 2.48 ± 0.46 to C. glabrata). However, in immunocompromised animals, C. krusei causes death in the whole group up to 7 days, instead, C. glabrata causes only a low increase in the infection degree (Log CFU/g = 6.98 ± 0.48). ii) The analytical methods of HPLC-UV and LC-MS/MS to VRC quantification were validated. Linearity was between 50 - 2500 range ng/mL (r > 0.98) for both methods. The intra and inter-day precision assays were > 94.9 e 95.8 %, for microdialysate using LC-UV and > 87.5 e 92.3 % using LCxx MS/MS for plasma, respectively. The accuracy was > 89.1 % for HPLC-UV and > 88.4 % for LC-MS/MS. iii) The evaluation of VRC by microdialysis showed that recovery is concentration independent (0.1–2 μg/mL). VRC, however, due to its moderate lipophilic characteristic, binds to the microdialysis system tubing’s, generating differences between recoveries determined by loss (retrodialysis) and gain (dialysis) in vitro methods, which could be corrected after determination of drug’s binding coefficient to the system. The in vivo recovery determined after correction of system binding was 24.5 ± 2.8 %. iv) VRC plasma profiles analysis obtained from Wistar rats after oral administration showed a nonlinear behavior, compatible with saturable elimination. The compartmental evaluation of i.v. profiles in different doses, employing the a compartment model with Michaelis-Menten elimination, allowed to determine the Michaelis-Menten constant (KM) of 0.58 μg/mL and the maximum velocity (VM) of 2.63 μg/h, in average. The simultaneous modeling of oral (40 mg/kg) and iv (10 mg/kg) plasma data allowed the determination of the oral bioavailability of VRC in rats, equal to 82.8%. v) The VRC renal penetration fraction, determined by microdialysis in healthy and infected rats, was 0.34 ± 0.01, similar to the free unbound fraction in plasma (0.34), showing that VRC free renal concentration levels are similar to the unbound plasma concentrations and that did not change due the infection associated to Candida sp. vi) The parameters of PK-PD modeling of VRC effect against Candida species in the in vitro experimental infection model obtained were: EC50 de 2.97 μg/mL and Kmax = 0.203 h−1 to C. albicans and EC50 of 3.47 μg/mL and Kmax = 0.51 h−1 to C. krusei. There is a statistical difference only in Kmax value for the two species (α = 0.05), showing a higher susceptibility of C. krusei to VRC. The PK/PD Emax modified model employed was able to describe adequately the growth inhibition profiles of Candida sp in function of time, for all VRC dosing regimens evaluated, and can be used for therapy optimization with this drug.
156

Modelagem farmacocinética-farmacodinâmica da piperacilina em ratos imunodeprimidos infectados com Escherichia coli

Araújo, Bibiana Verlindo de January 2002 (has links)
Objetivos: Avaliar a adequabilidade do modelo farmacocinético-farmacodinâmico (PK-PD) (NOLTING et al., 1996b) para modelar o efeito bactericida da piperacilina (PIP) em ratos Wistar infectados experimentalmente com Escherichia coli ATCC 25922. Metodologia: Experimentos de Farmacocinética: Determinou-se as concentrações plasmáticas totais e livres teciduais de PIP, através de microdiálise (MD), após administração de 240 mg/kg i.v. bolus a ratos Wistar granulocitopênicos (ciclofosfamida) infectados no músculo esquelético (105 UFC/mL) com E. coli. As amostras de plasma e de MD foram analisadas por CLAE. As sondas de MD foram calibradas por retrodiálise. Experimentos de Farmacodinâmica: Os animais imunodeprimidos e infectados foram tratados com PIP nas doses de 120 ou 240 mg/kg, em intervalos de 4/4, 6/6 e 8/8 horas por 24 h. Em tempos pré-determinados, os animais foram sacrificados (n = 3/tempo), o músculo infectado foi retirado, homogeneizado e o número de UFC/mL foi determinado em placas de ágar-sangue, após diluições sucessivas. Um grupo não tratado foi utilizado como controle. Modelagem PK-PD: A partir dos dados farmacocinéticos e farmacodinâmicos obtidos, avaliou-se efeito de morte bacteriana em função do tempo com o auxílio do programa de regressão não-linear SCIENTIST® v.2.0. Resultados e Discussão: Os parâmetros farmacocinéticos após a administração de PIP (240 mg/kg) foram t½ de 40 ± 8 min; CL de 0,46 ± 0,021 (L/h/kg) e um Vdss de 0,30 ± 0,06 L/kg. O perfil de PIP livre tecidual foi previsto a partir dos parâmetros plasmáticos utilizando ajuste simultâneo dos dados de plasma e tecido e um fator de proporcionalidade de 0,342 ± 0,101. Os parâmetros do modelo PK-PD obtidos foram: EC50 de 1,31 ± 0,27 μg/mL e kmax 1,39 ± 0,20 h-1. Os valores dos parâmetros da modelagem PK-PD obtidos in vivo diferiram dos descritos na literatura para o mesmo antibiótico e bactéria quando simulados in vitro. Conclusões: O modelo Emax-modificado descreveu os perfis de crescimento e morte bacteriana em função do tempo obtidos nas diferentes posologias testadas sendo adequado para modelagem PK-PD da piperacilina nas condições experimentais investigadas. / Purpose: The objective of this study was to model the killing effect of a β-lactam antibiotic, piperacillin (PIP), in neutropenic and E. coli ATCC 25922 infected rats after different dosing regimens using a modified Emax PK-PD model. Methodology: Pharmacokinetic studies: Total plasma and free tissue concentrations of PIP, determined by microdialysis, were investigated after i.v. bolus of 240 mg/kg of the drug to immunecompromised (cyclophosphamide) and E. coli infected (107 CFU) Wistar rats. Microdialysis probes recoveries were determined by retrodialysis. Plasma and tissue samples were analyzed by HPLC. Pharmacodynamic studies: The infected rats were treated with iv bolus PIP 120 mg/kg or 240 mg/kg q8h, q6h, q4h. Three animals were sacrificed at predetermined times up to 24 hours. The infected muscle was removed, homogenized and the number of CFU/mL was determined by plate counting after 24 hours of incubation at 37ºC. A control group without treatment was used. PK-PD modeling: PIP killing effect as a function of time was fitted using the Emax-modified model with the aid of a non-linear regression computer program SCIENTIST® v.2.0. Results and Discussion: The pharmacokinetic parameters determined for PIP 240 mg/kg iv bolus were: t½ of 40 ± 8 min; CL of 0.46 ± 0.021 (L/h/kg) and Vdss of 0.30 ± 0.06 L/kg. Piperacillin free tissue levels were predicted using plasma data ina a simultaneous fitting with a proportionality factor of 0.342 ± 0.101. The parameters derived from PK-PD modeling were: bacterial killing rate (kmax) of 1.39 ± 0.20 h-1 concentration to produce 50% of de maximum effect (EC50) of 1.31 ± 0.27 μg/mL. The PK-PD parameters determined in vivo were different from those reported for the same bacteria and drug in vitro. Conclusions: The Emax model adequately described PIP antibacterial effect in animals for the different dosing regimens investigated.
157

Predictors of brain injury after experimental hypothermic circulatory arrest:an experimental study using a chronic porcine model

Pokela, M. (Matti) 10 October 2003 (has links)
Abstract There is a lack of reliable methods of evaluation of brain ischemic injury in patients undergoing cardiac surgery. The present study was, therefore, planned to evaluate whether serum S100β protein (I), brain cortical microdialysis (II), intracranial pressure (III) and electroencephalography (EEG) (IV) are predictive of postoperative death and brain ischemic injury in an experimental surviving porcine model of hypothermic circulatory arrest (HCA). One hundred and twenty eight (128) female, juvenile (8 to 10 weeks of age) pigs of native stock, weighing 21.0 to 38.2 kg, underwent cardio-pulmonary bypass prior to, and following, a 75-minute period of HCA at a brain temperature of 18°C. During the operation, hemodynamic, electrocardiograph and temperature monitoring was performed continuously. Furthermore, metabolic parameters were monitored at baseline, end of cooling, at intervals of two, four and eight hours after HCA and before extubation. Electroencephalographic recording was performed in all animals, serum S100β protein measurement in 18 animals, cortical microdialysis in 109 animals, and intracranial pressure monitoring in 58 animals. After the operation, assessment of behavior was made on a daily basis until death or elective sacrifice on the seventh postoperative day. All four studies showed that these parameters were predictive of postoperative outcome. Animals with severe histopathological injury had higher serum S100β protein levels at every time interval after HCA. Analysis of cortical brain microdialysis showed that the lactate/glucose ratio was significantly lower and the brain glucose concentration significantly higher among survivors during the early postoperative hours. Intracranial pressure increased significantly after 75 minutes of HCA, and this was associated with a significantly increased risk of postoperative death and brain infarction. A slower recovery of EEG burst percentage after HCA was significantly associated with the development of severe cerebral cortex, brain stem and cerebellum ischemic injury. In conclusion, serum S100β protein proved to be a reliable marker of brain ischemic injury as assessed on histopathological examination. Cerebral microdialysis is a useful method of cerebral monitoring during experimental HCA. Low brain glucose concentrations and high brain lactate/ glucose ratios after HCA are strong predictors of postoperative death. Increased intracranial pressure severely affected the postoperative outcome and may be a potential target for treatment. EEG burst percentage as a sum effect of anesthetic agent and ischemic brain damage is a useful tool for early prediction of severe brain damage after HCA. Among these monitoring methods, brain cortical microdialysis seems to be the most powerful one in predicting brain injury after experimental hypothermic circulatory arrest.
158

Extraction and analysis of interstitial fluid, and characterisation of the interstitial compartment in kidney disease

Ebah, Leonard January 2012 (has links)
Kidney failure results in fluid and toxin accumulation within body fluid compartments, contributing to the excess mortality seen in this condition. Such uremic toxins have been measured in plasma, with levels assumed to reflect extraplasmatic concentrations such as in interstitial fluid (ISF). ISF is separated from plasma by nanometre-order microvascular pores; toxins may not circulate “freely” between the two compartments. This work set out to characterise the ISF in uremic subjects, with the hypothesis that there may be differences with plasma. Any such difference may be clinically relevant, owing to the much larger size of the ISF compartment, its proximity to cell metabolic processes, and its expansion in renal impairment.We used a modified microdialysis technique to successfully sample subcorneal ISF of some the uremic toxins (urea, creatinine, urate, phosphate). Reverse iontophoresis (RI) was also used as a non-invasive technique to sample epidermal ISF of urea. Hollow microneedles were developed and their ability to extract ISF tested in CKD patients and controls. The mechanical properties (pressure, volume, permeability) and biochemical composition (proteomic and metabolomic profiles) of the interstitial compartment were also investigated.Microdialysis and RI performed very well as interstitial uremic toxin sampling techniques. Small differences were seen in steady states between ISF and plasma urea, creatinine, phosphate and urate, with slightly lower ISF levels. Dialysis seemed to enhance this difference, with a lag in the clearance of ISF toxins seen in some patients, most remarkable with phosphate. Metabolomic analysis identified several uremic toxins in ISF, whilst proteomics found some significant differences between the two compartments, with toxins like beta-2 microglobulin occurring in ISF only. Microneedle arrays successfully extracted ISF in 68.8% of patients with oedema. Successful extraction of ISF with microneedles occurred mainly in oedematous patients, who were found to have raised interstitial pressures (ISP) and volumes. ISP correlated significantly with body fluid volumes and seemed time-dependent, lower in more chronic oedema. ISP and volumes also correlated with the oedema depitting time (after thumb pressure), a potential novel parameter that probably relates to tissue hydraulic conductivity and hence volume status and fluid mobility within the interstitium.This study demonstrates that interstitial fluid may need to be considered as a separate active compartment in patients with renal dysfunction, with a different “uremic" composition and unique pathophysiological characteristics that cannot be explained by blood compartment based measurements alone. There is a need for more studies, to further characterise this compartment and elucidate its importance.
159

Peripheral Dopamine 2 Receptors Both Modulate Central Dopamine Release and Adopt in a Similar Manner to that of Central Dopamine 2 Receptors

Obray, J. Daniel 24 April 2020 (has links)
Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment and of those who do many will relapse. This highlights a need to develop new treatments for alcohol use disorder that are both more accessible and more effective. This dissertation characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and function following an acute dose of ethanol. This was done by using microdialysis to measure dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the ventral tegmental area to measure dopamine neuron activity and place conditioning to measure the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally, intravenous dopamine produced a modest conditioned place preference. Domperidone, a peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally modulated the sedating effects of ethanol depending on the dose of ethanol administered. The involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells. Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can enhance dopamine levels in the nucleus accumbens and that this effect has relevance in understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful biomarker for central dopamine function.
160

Peripheral Dopamine 2 Receptors Both Modulate Central Dopamine Release and Adopt in a Similar Manner to that of Central Dopamine 2 Receptors

Obray, J. Daniel 24 April 2020 (has links)
Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment and of those who do many will relapse. This highlights a need to develop new treatments for alcohol use disorder that are both more accessible and more effective. This dissertation characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and function following an acute dose of ethanol. This was done by using microdialysis to measure dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the ventral tegmental area to measure dopamine neuron activity and place conditioning to measure the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally, intravenous dopamine produced a modest conditioned place preference. Domperidone, a peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally modulated the sedating effects of ethanol depending on the dose of ethanol administered. The involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells. Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can enhance dopamine levels in the nucleus accumbens and that this effect has relevance in understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful biomarker for central dopamine function.

Page generated in 0.0244 seconds